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Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients
with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in
the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the
effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients.
Methods: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely
methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten
injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an
acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above
accompanied by three cycles of acupuncture). Of the patients, 98 out of 104 completed the treatment and follow-ups.
There were 49 patients in each group. The evaluating parameters included the visual analogue scale (VAS) pain score,
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire
scores, and electromyographic (EMG) nerve conduction velocity (NCV) determinations. We evaluated the changes of
the parameters in each group before and after the therapies and made a comparison between the two groups.
Results: After 84 days (three cycles) of therapy, the pain was significantly alleviated in both groups, with a significantly
higher decrease in the acupuncture treated group (P < 0.01). The patients’ daily activity evaluated by Fact/GOG-Ntx
questionnaires significantly improved in the Met + Acu group (P < 0.001). The NCV in the Met + Acu group improved
significantly while amelioration in the control group was not observed.
Conclusions: The present study suggests that acupuncture combined with methylcobalamin in the treatment of CIPN
showed a better outcome than methylcobalamin administration alone.
Trial registration: China Clinical Trials Register (registration no. ChiCTR-INR-16009079, registration date August 24, 2016).
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Background
Multiple myeloma (MM) is a common hematologic
malignancy and the incidence rate increases every year
worldwide. Proteasome inhibitors such as bortezomib are
commonly used for the initial treatment, as well as
consolidation and maintenance therapies [1, 2]. However,
chemotherapy-induced peripheral neuropathy (CIPN) dur-
ing MM treatments is a dose-limiting side effect and the
incidence rate of bortezomib-related neuropathy has been
reported to be 30–60% [3, 4]. Common peripheral neur-
opathy symptoms in the distal limbs are symmetric
sensory dysfunctions, with a variety of sensory losses such
as glove or sock-shaped distribution, possibly associated
with paresthesia and excessive pain. Other symptoms are
movement disorders such as muscle weakness, muscle
atrophy, diminished or disappeared limb and tendon re-
flexes, inability to fasten buttons as well as walking diffi-
culties. In addition, autonomic nervous system disorders
such as orthostatic hypotension, arrhythmia, bradycardia
and other symptoms may occur.
Peripheral neuropathy is a key factor for drug dose
and application duration restrictions, because patients
often cannot tolerate symptoms, leading to a reduced
drug dose and number of therapy cycles or even discon-
tinuation of therapy. Therefore, reducing CIPN in MM
treatments is a critical point for improving a patient’s
quality of life and treatment outcome.
The therapy choices for CIPN treatments in MM
patients are very limited but include neurotrophic drug
treatment with methylcobalamin administered orally or
as an intramuscular injection. The methylation of a
functional group in methylcobalamin, a coenzyme of
vitamin b12, enables drug availability and thereby pro-
motes the metabolism of nucleic acids, proteins and
lipids in nerve tissues. In addition, methylcobalamin
stimulates cell lecithin synthesis, repairs damaged myelin
and thereby improves nerve conduction velocity. First
line treatments of neuropathic pain includes gabapentin,
5% lidocaine patches and opioid analgesics such as tram-
adol hydrochloride. Second line drugs include lamotri-
gine, carbamazepine and amitriptyline, as well as other
antidepressants [5]. These drugs have various side ef-
fects, such as sedation, ataxia, dizziness, double vision,
nausea and indigestion. The commonly used analgesics
against neuropathic pain may work, but viable treatment
options often do not completely relieve the symptoms.
However, when grades III-IV neurotoxicity occurs, the
neurological symptoms will be partially relieved once the
chemotherapy drug doses or therapy cycles are reduced,
but inevitably the therapeutic effect on MM is also
diminished.
Acupuncture, first mentioned in the 5th century BC, is
part of traditional Chinese medicine and its effects, espe-
cially in pain control, have been confirmed in clinical
trials, which led to the usage of acupuncture also in
many other countries. A questionnaire of 180 patients
with peripheral neuropathy showed that 30% of them
choose acupuncture as an alternative method of pain
control [6].
Studies on humans and animals have identified the
neurochemical basis of acupuncture effects on brain
functions. Acupuncture can stimulate receptors or cause
the regular discharge of nerve fibers, leading to periph-
eral and central nervous system activation, resulting in
the release of a variety of neurotransmitters [7]. The spe-
cific effect of acupuncture depends on the acupuncture
point choice, the form of stimulation and the duration
of the therapy [8]. Chinese acupuncture, an adjunct ther-
apy, has gained increased attention in the medical field
at home and abroad in recent years. Prospective clinical
trials have demonstrated that acupuncture was effective
in treating pain caused by diabetes as well as HIV virus
infections [9–17], and various clinical trials have shown
the effect of acupuncture in alleviating neuropathic pain in
cancer patients [18, 19]. In addition, a case series has
proven the efficacy of body acupuncture in treating
patients with CIPN [20], and a pilot study demonstrated
that acupuncture improved nerve conduction in peripheral
neuropathy [21]. In recent studies, statistically and clinic-
ally significant reductions in subjective measurements of
bortezomib-induced peripheral neuropathy (BIPN) were
observed after acupuncture treatment [22, 23]. However,
to date, there have been no randomized controlled clinical
research to analyze the effectiveness of acupuncture in
treating CIPN of MM patients.
Since previous research showed that acupuncture had
good treatment effects on peripheral neuropathy of
diabetes and HIV/AIDS patients, we hypothesized that




Four hundred twelve patients diagnosed with MM
(not limited to the type or stage) were hospitalized
for chemotherapy in our center between May 2010
and May 2014. The inclusion criteria were: diagnosed
MM; baseline without peripheral neuropathy and per-
ipheral neuropathy appeared after chemotherapy at
grade II or above (according to the NCI CTCAE ver-
sion 3.0 neuropathy severity assessment) [24]; EMG
examinations showing disturbances in median and
peroneal nerve conduction; platelet count greater than
30 × 109/L; no history of methylcobalamin allergy;
having discontinued chemotherapy within 3 months
and were willing to accept new therapy and sign an
informed consent form. The exclusion criteria were:
pregnancy; severe heart, liver or kidney dysfunction
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or other severe diseases (e.g. malignancies); neuropathy
caused by tumor compression, nutritional disorders or in-
fections or causes other than chemotherapy; refusal to
sign the informed consent form. The remaining 104 MM
patients who met the inclusion criteria in our center were
randomly divided into two groups. 98 out of 104 com-
pleted the treatment and follow-up. In the Met + Acu
group, two patients stopped acupuncture treatment
because of scheduled stem cell transplantation and one
patient was lost to follow up. In the control group, two pa-
tients were lost to follow up and one patient died of severe
pneumonia. Finally, 49 patients who were treated with
acupuncture combined with methylcobalamin (Met +
Acu group) and 49 patients only treated with methylco-
balamin (control group) were included for the outcome
analysis (Fig. 1).
Treatments
The control group received only 500 μg methylcobala-
min intramuscularly every other day, 10 times and there-
after 500 μg orally three times a day. The Met + Acu
group received the same methylcobalamin application
with an additional acupuncture protocol according to
the neurohumoral mechanism theory of acupuncture
[25]. In all cases, the acupuncture was performed by the
same senior physician who had acupuncture experience
for 15 years. Every patient received needles bilaterally in
the following acupoints: Supine position: bilateral Taichong
(LR3), Xiangu (ST43), Zulinqi (GB41), Sanyinjiao (SP6),
Zusanli (ST36), Xuehai (SP10), Tianshu (ST25); Prone pos-
ition: Dazhui (GV14), Shenzhu (GV12), Shendao (GV11),
Zhiyang (GV9), Feishu (BL13), Geshu (BL17) and Feiyang
(BL58) (Figs. 2 and 3). The first acupuncture was in prone
position acupoints with needle retention, followed by su-
pine position acupoints. An aseptic procedure was exe-
cuted with disposable, stainless steel 30–32 gauge needles,
which were implanted to a depth of 0.3–1.0 in. into the
acupoints until the patient felt dull pain or de qi [26], and
were left in place for 30 min. The acupunctures were done
daily for 3 days, then once every alternate day for 10 days
as a treatment cycle. Each cycle was repeated every 28 days
and the complete treatment included three cycles.
Evaluation standards
The validated Ntx extension of the Functional Assessment
of Cancer Therapy/Gynaecologic Oncology Group/
Neurotoxicity (FACT/GOG-Ntx) questionnaire [27] was
used to investigate the patients’ daily activities and evalu-
ate the degree of neuropathy. The questionnaire included
7 questions about physical well-being, 7 questions about
social/family well-being, 6 questions about emotional
well-being, 7 questions about functional well-being and 9
questions about additional concerns. The VAS pain score
[28] was used to assess neuralgia. The bilateral NCV of
the arms and legs was determined by the same profes-
sional technician before and after treatment using Nicolet
Viasys Viking Select EMG NCS equipment from the USA.
Skin surface electrodes were used to record the average of
the motor conduction velocities (MCV) of the bilateral
median and peroneal nerves as well as sensory nerve con-
duction velocities (SCV) of the bilateral median and the
sural nerves. All evaluation measurements were carried
out before and after treatments.
Fig. 1 Flow chart of the present study
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Fig. 2 Scheme of acupuncture points on the legs, feet and ventral upper body
Fig. 3 Scheme of acupuncture points on the dorsal upper body
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CIPN severity assessment
CIPN was categorized according to the grading system
published by Postma and Heimans (2000) [29].
Statistical analysis
Statistical analyses were performed using GraphPad.
Prism 5.01 statistical software. Assuming a mean value
of the VAS score change was 2, standard deviation was
0.5 before and after treatment in the Met + Acu group,
while the mean value of the VAS score change was 1.6;
the standard deviation was 0 in the control group. A
sample size of 41 in each group was considered to
provide 95% power for detecting significant differences
in the two groups (two-sided, α = 5%). To account for a
20% dropout, 104 patients in total (52 in each group)
were included. The results are shown as the mean ±
SEM. Between the two groups, single-factor analysis of
variance (one-way ANOVA) and Tukey’s test were used
for analyses while an independent sample t-test was
used in one group. Statistical significance was considered
at P < 0.05.
Results
The characteristics of the treatment and control groups
are shown in Table 1. There were no statistically signifi-
cant differences between the 2 groups regarding the
baseline characteristics.
VAS pain scores
After 3 cycles of therapy, the pain was significantly miti-
gated in the Met + Acu group, while the VAS pain scores
decreased in 85.7% of the patients (42/49). Pain in the
control group was also eased and the VAS pain scores de-
creased in 77.6% of these patients (38/49). However, the
VAS pain scores in the Met + Acu group decreased more
significantly compared to the control group (P < 0.01)
(Table 2).
Quality of life scores
Evaluated by FACT/the GOG-Ntx questionnaire scores,
the nervous system symptoms improved significantly in
the Met + Acu group (P < 0.001) after therapy, but not in
the control group (P > 0.05), and the improvement was
more significant in the Met + Acu group (P < 0.05)
(Table 3).
Nerve conduction velocity
After treatments, there was no significant difference in
MCV improvement in the Met + Acu group compared to
the control group (P > 0.05). In contrast, before and after
treatment in the Met + Acu group, the MCV of the bilat-
eral median and peroneal nerves improved significantly
after the acupuncture therapy (P < 0.05 and P < 0.01, re-
spectively), while there was no obvious change in the
control group (P > 0.05). The SCV of the sural nerve in
the Met + Acu group improved significantly (P < 0.01), but
there was no obvious change in the bilateral median nerve
after the Met + Acu therapy (P > 0.05) (Table 4). Changes
in the SCV of the sural and median nerve in the control
group were not statistically significant (P > 0.05). Com-
paring the SCV after therapy between the two groups,
the SCV of the sural nerve in the Met + Acu group was
significantly superior to the control group (P < 0.01)
(Table 4).
These data suggested that the treatment of Met + Acu
improved the MCV and SCV (except for the median
nerve SCV) in the Met + Acu group, while a solely
methylcobalamin treatment in the control group had no
effect on SCVs or MCVs.
Table 1 Baseline Characteristics of the MM patients












Light chain (Kappa/lambda) 9 11*
PN Grade (CTCAE)
Grade 2 20 19*
Grade 3 25 27*
Grade 4 4 3*
VAS scores 5.57 ± 0.26 5.50 ± 0.24*
FACT/the GOG-Ntx scores 36.48 ± 0.47 36.63 ± 0.55*
*P > 0.05, compared between the Met + Acu and control groups before therapy
Table 2 VAS pain scores before and after treatment
Group n Before therapy After therapy
Met + Acu Group 49 5.57 ± 0.257 3.23 ± 0.170***△△
Control Group 49 5.50 ± 0.244 4.25 ± 0.197***
***P < 0.001, compared before and after therapy
△△P < 0.01, compared between the Met + Acu and control groups
Table 3 FACT/the GOG-Ntx questionnaire scores before and
after treatment
Group n Before therapy After therapy
Met + Acu Group 49 36.48 ± 0.470 32.98 ± 0.542*** △
Control Group 49 36.63 ± 0.551 35.17 ± 0.518
***P < 0.001, compared before and after therapy
△P < 0.05, compared between the Met + Acu and control groups
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Discussion
To the best of our knowledge, this is the first random-
ized, controlled, prospective study on the use of acu-
puncture in the treatment of multiple myeloma patients
with CIPN grades II–IV [29]. After 84 days (three cycles)
of therapy, although methylcobalamin treatment alone
was helpful in relieving pain and improving the quality
of life, the study showed that acupuncture combined
with methylcobalamin for the treatment of CIPN was
significantly superior in providing pain relief (VAS pain
scores) and life quality improvement (FACT/GOG-Ntx
questionnaire scores). Our results are in agreement with
previous reports that acupuncture has a beneficial effect
on peripheral neuropathy and are consistent with the
study of Schroder et al [21]; nerve conduction in the
sural nerve was improved best in our study [20, 21]. The
SCV of the median nerve did not change after a Met
+ Acu therapy, which might reflect the choice of
acupuncture points, indicating that they have a major
impact on the therapeutic effects [30].
According to traditional Chinese medicine (TCM) the-
ory, the symptoms of CIPN are caused by the body’s fail-
ure to direct Qi (vital energy) and blood to the four limbs,
resulting in sensory symptoms and impaired limb function
while acupuncture restores body Qi and blood, and directs
their flow to the extremities [20], which is supported by a
studies which demonstrated that acupuncture led to vaso-
dilation and enhanced blood perfusion [31, 32].
It has been suggested, that bortezomib mainly affects
the dorsal root ganglia (DRG) of the primary sensory
neurons leading to disturbed transcription, nuclear pro-
cessing and transport, as well as cytoplasmic translation of
mRNAs and histopathological changes in the DRG neu-
rons. In addition, neural survival is compromised due to
inhibition of nerve growth factor (NGF) transcription [33]
and a highly significant correlation between the decrease
in circulating levels of NGF and the severity of CIPN has
been reported (P < 0.001) [34].
Previous animal studies noted that both protein and
mRNA levels of glial cell line-derived neurotrophic factor
(GDNF) and GDNF family receptor alpha-1 (GFRalpha-1)
were upregulated in the DRGs after acupuncture [35].
However, another recent study found that acupuncture
significantly changed the expression of 17 hypothalamic
proteins in a rat neuropathic pain model [36]. Taken
together, though enhanced blood perfusion as result of
acupuncture has been proven in humans, other mecha-
nisms of specific gene expression changes have so far
only been investigated in animal models. It is also un-
clear whether acupuncture leads to histological changes,
which might be evaluated in future studies with biopsy-
analyses [21]. In addition, since the acupoints were
established in TCM several centuries ago, analysis of
acupoints with advanced techniques like MRI may lead
to improved results.
There were no obvious unexpected side effects during
the treatments of both groups, and puncture site infec-
tions or bleeding did not occur during the acupuncture
process, suggesting that acupuncture is a safe treatment
for CIPN in MM patients.
Conclusions
In conclusion, our study revealed, in agreement with
previous pilot studies, that acupuncture for the treat-
ment of CIPN as adjunct therapy leads to a significantly
improved outcome in MM patients.
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Table 4 Nerve conduction velocity before and after treatment
Group n MCV SCV
Bilateral median nerve Peroneal nerve Bilateral median nerve Sural nerve
Met + Acu group Before treatment 49 49.81 ± 0.78 44.59 ± 0. 78 49.58 ± 0.73 43.99 ± 0.63
After treatment 49 52.84 ± 0.81* 47.88 ± 0.67** 51.51 ± 0.64 46.87 ± 0.77**△△
Control group Before treatment 49 50.43 ± 0.70 45.09 ± 0.71 49.98 ± 0.94 44.11 ± 0.60
After treatment 49 51.05 ± 0.60 45.42 ± 0.76 50.40 ± 0.79 43.61 ± 0.51
*P < 0.05, compared before and after therapy
**P < 0.01, compared before and after therapy
△△P < 0.01, compared between the Met + Acu and control groups
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